Q1 Earnings Estimate for CRBU Issued By HC Wainwright

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Caribou Biosciences in a research note issued on Thursday, October 8th. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of ($0.11) for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS and Q4 2027 earnings at ($0.05) EPS.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.08. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%.The firm had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.28 million.

Several other equities research analysts have also recently issued reports on CRBU. Leerink Partners reaffirmed a “market perform” rating and set a $1.00 target price (down from $4.00) on shares of Caribou Biosciences in a research note on Wednesday. Bank of America reduced their target price on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Royal Bank Of Canada downgraded shares of Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 price target on the stock. in a research note on Wednesday. Wall Street Zen lowered shares of Caribou Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Finally, Brookline Capital Markets cut shares of Caribou Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.50.

Caribou Biosciences Stock Performance

NASDAQ CRBU opened at $0.48 on Friday. The business has a fifty day moving average price of $1.43 and a 200 day moving average price of $1.74. The company has a market cap of $51.59 million, a P/E ratio of -0.45 and a beta of 2.31. Caribou Biosciences has a one year low of $0.45 and a one year high of $3.54.

Institutional Trading of Caribou Biosciences

Several large investors have recently added to or reduced their stakes in CRBU. CTC Alternative Strategies Ltd. acquired a new stake in shares of Caribou Biosciences in the 1st quarter worth $29,000. Westmount Partners LLC purchased a new position in shares of Caribou Biosciences during the 1st quarter worth $37,000. Next Capital Management LLC acquired a new position in shares of Caribou Biosciences during the 2nd quarter valued at about $35,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Caribou Biosciences in the second quarter valued at about $41,000. Finally, Spark Investment Management LLC acquired a new stake in Caribou Biosciences during the second quarter worth about $42,000. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Caribou Biosciences

Here are the key news stories impacting Caribou Biosciences this week:

• Neutral Sentiment: Leerink Partners downgraded Caribou from “outperform” to “market perform” and set a $1 price target. Although the target implies substantial potential upside from recent levels, the rating change signals reduced confidence in the company’s near-term prospects. Leerink Partners Downgrades Caribou Biosciences to Market Perform
• Negative Sentiment: HC Wainwright & Co. cut its rating from “buy” to “neutral,” adding to the growing analyst caution surrounding Caribou’s pipeline and strategic direction. HC Wainwright Downgrades Caribou Biosciences
• Negative Sentiment: RBC downgraded Caribou from “outperform” to “sector perform” and slashed its price target to $1 from $10, retaining a speculative-risk designation. The steep target reduction reflects the expected impact of abandoning key development programs. RBC Downgrades Caribou Biosciences
• Negative Sentiment: Caribou said it would halt two CAR-T programs and cut its workforce, actions that raise questions about the company’s remaining pipeline and future operating strategy. Caribou to Halt CAR-T Programs and Cut Workforce
• Negative Sentiment: The company’s decision to explore strategic alternatives and discontinue CAR-T programs triggered a sharp selloff, while Brookline Capital Markets separately downgraded the shares from “buy” to “hold.” Caribou Shares Fall After Strategic Review
• Negative Sentiment: Coverage characterizing the company’s off-the-shelf cell-therapy effort as reaching the “end of the road” reinforces concerns that Caribou’s clinical strategy has materially narrowed. Caribou’s Cell-Therapy Strategy

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.